Immunotherapy plus chemo shows promise for pancreatic cancer before surgery

NCT ID NCT06177522

Not yet recruiting Disease control Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can help shrink pancreatic tumors before surgery. About 30 people with resectable pancreatic cancer will receive the combination, and researchers will measure how many tumors are completely removed and how safe the treatment is. The goal is to improve outcomes for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug) combined with chemotherapy (albumin-bound paclitaxel and gemcitabine)
What this could lead to: If successful, this could offer a more effective pre-surgery treatment to shrink pancreatic tumors and improve complete removal rates.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply widely. Immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOADJUVANT THERAPY PANCREATIC CANCER

Contacts and locations

Locations

Wang Sizhen

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.